{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:29:08Z","timestamp":1792517348964,"version":"4.5.0"},"reference-count":27,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["GZ-2014-11295"],"award-info":[{"award-number":["GZ-2014-11295"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Gaucher disease (GD) is caused by mutations in the GBA gene, leading to deficient activity of the lysosomal enzyme glucocerebrosidase. Among all the symptoms across various organ systems, bone disease is a major concern as it causes high morbidity and reduces quality of life. Enzyme replacement therapy (ERT) is the most accepted treatment; however, there are still unmet needs. As an alternative, substrate reduction therapy (SRT) was developed using glucosylceramide synthase inhibitors. In the current study, the effects of ERT vs. SRT were compared, particularly the immunological and bone remodeling aspects. GD subjects were divided into three cohorts based on their treatment at initial visit: ERT, SRT, and untreated (UT). Immunophenotyping showed no significant immune cell alterations between the cohorts. Expression of RANK\/RANKL\/Osteoprotegerin pathway components on immune cells and the secreted markers of bone turnover were analyzed. In the ERT cohort, no significant changes were observed in RANK, RANKL or serum biomarkers. RANKL on T lymphocytes, Osteopontin and MIP-1\u03b2 decreased with SRT treatment indicating probable reduction in osteoclast activity. Other secreted factors, Osteocalcin and RANKL\/Osteoprotegerin did not change with the treatment status. Insights from the study highlight personalized differences between subjects and possible use of RANK pathway components as markers for bone disease progression.<\/jats:p>","DOI":"10.3390\/biom10040526","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T05:52:30Z","timestamp":1585720350000},"page":"526","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-6284","authenticated-orcid":false,"given":"Renuka P.","family":"Limgala","sequence":"first","affiliation":[{"name":"Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), Fairfax, VA 22030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[{"name":"Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), Fairfax, VA 22030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2014.02.005","article-title":"Gaucher disease","volume":"4","author":"Nagral","year":"2014","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ymgme.2011.08.004","article-title":"Therapeutic approaches to bone pathology in Gaucher disease: Past, present and future","volume":"104","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-pathol-011110-130203","article-title":"Disorders of bone remodeling","volume":"6","author":"Feng","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3389\/fimmu.2018.00657","article-title":"Immunoporosis: Immunology of Osteoporosis-Role of T Cells","volume":"9","author":"Srivastava","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fendo.2019.00236","article-title":"Updates on Osteoimmunology: What\u2019s New on the Cross-Talk Between Bone and Immune System","volume":"10","author":"Ponzetti","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"192761","DOI":"10.1155\/2015\/192761","article-title":"Pathogenesis of Bone Alterations in Gaucher Disease: The Role of Immune System","volume":"2015","author":"Mucci","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1615\/CritRevOncog.2013004503","article-title":"Immunological cells and functions in Gaucher disease","volume":"18","author":"Pandey","year":"2013","journal-title":"Crit. Rev. Oncog."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1006\/bcmd.1999.0237","article-title":"T cell numbers relate to bone involvement in Gaucher disease","volume":"25","author":"Lacerda","year":"1999","journal-title":"Blood Cellsmolecules Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1359\/jbmr.060604","article-title":"RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone","volume":"21","author":"Atkins","year":"2006","journal-title":"J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-4419-1050-9_9","article-title":"Novel functions of RANK(L) signaling in the immune system","volume":"658","author":"Leibbrandt","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/0192623317735316","article-title":"Bone and the Immune System","volume":"45","author":"Weitzmann","year":"2017","journal-title":"Toxicol. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/1060028013500469","article-title":"Gaucher disease and its treatment options","volume":"47","author":"Bennett","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1002\/ajh.24056","article-title":"Long-term treatment outcomes in Gaucher disease","volume":"90","author":"Charrow","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_15","first-page":"315","article-title":"Optimal therapy in Gaucher disease","volume":"6","year":"2010","journal-title":"Clin. Risk Manag"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1310\/hpj5107-553","article-title":"Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options","volume":"51","author":"Holsopple","year":"2016","journal-title":"Hosp. Pharm."},{"key":"ref_17","first-page":"82","article-title":"Management of Gaucher disease: Enzyme replacement therapy","volume":"12","author":"Zimran","year":"2014","journal-title":"Pediatric Endocrinol. Rev.: Per"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Limgala, R.P., Ioanou, C., Plassmeyer, M., Ryherd, M., Kozhaya, L., Austin, L., Abidoglu, C., Unutmaz, D., Alpan, O., and Goker-Alpan, O. (2016). Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168135"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bcmd.2016.02.003","article-title":"Persistent immune alterations and comorbidities in splenectomized patients with Gaucher disease","volume":"59","author":"Sonder","year":"2016","journal-title":"Blood Cellsmolecules Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbadis.2007.04.002","article-title":"Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease","volume":"1772","author":"Voerman","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","article-title":"Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: Effect on incidence of avascular necrosis","volume":"147","author":"Mistry","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13023-014-0112-x","article-title":"Modelling Gaucher disease progression: Long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications","volume":"9","author":"Biegstraaten","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.21280","article-title":"A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase","volume":"83","author":"Weinreb","year":"2008","journal-title":"Am. J. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-016-0413-3","article-title":"Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients","volume":"11","author":"Smid","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13256-016-1147-5","article-title":"Combination therapy in a patient with chronic neuronopathic Gaucher disease: A case report","volume":"11","author":"Ceravolo","year":"2017","journal-title":"J. Med. Case Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13256-017-1541-7","article-title":"Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: Two case reports","volume":"12","author":"Amato","year":"2018","journal-title":"J. Med. Case Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI200319190","article-title":"Osteopontin: A bridge between bone and the immune system","volume":"112","author":"Gravallese","year":"2003","journal-title":"J. Clin. Investig."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/4\/526\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:13:39Z","timestamp":1760174019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/4\/526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["biom10040526"],"URL":"https:\/\/doi.org\/10.3390\/biom10040526","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]}}}